🇪🇺 Cablivi in European Union

EMA authorised Cablivi on 30 August 2018

Marketing authorisation

EMA — authorised 30 August 2018

  • Application: EMEA/H/C/004426
  • Marketing authorisation holder: Ablynx NV
  • Local brand name: Cablivi
  • Indication: Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
  • Pathway: orphan
  • Status: approved

Read official source →

Cablivi in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is Cablivi approved in European Union?

Yes. EMA authorised it on 30 August 2018.

Who is the marketing authorisation holder for Cablivi in European Union?

Ablynx NV holds the EU marketing authorisation.